ClinicalTrials.gg
CompletedNCT03325816Updated Mar 16, 2021Results posted

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

A Phase 1/2 interventional study of Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate in Small Cell Lung Cancer and Small Cell Lung Cancer Extensive Stage, sponsored by Georgetown University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-16.

Sponsored by Georgetown University · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies testing nivolumab in Small Cell Lung Carcinoma — none open to participants now, 4 under way, none of them phase 3. Nivolumab · Small Cell Lung Carcinoma.

Enrollment
14th of 16
9 · median 23
Started
2017
with 4 others
Phase 1/2
2 of 16
none open now
Registered
6th of 16
by date
Lead sponsor
1 of 16
Georgetown University

Among the 16 studies testing nivolumab in Small Cell Lung Carcinoma, this one is the 14th largest by enrollment, is one of 5 that started in 2017, is one of 2 in phase 1/2, and was the 6th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

None of the 16 studies testing nivolumab in Small Cell Lung Carcinoma is open now. The open studies under Small Cell Lung Carcinoma, anywhere →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing nivolumab in Small Cell Lung Carcinoma as a file.
02

Study summary

This research study is being done to assess the safety and tolerability of study drugs, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) and nivolumab in subjects with small cell lung cancer or advanced or inoperable neuroendocrine tumor of the lung that has overexpressed somatostatin receptors (SSRT). Lutathera is an investigational radioactive agent that targets tumor cells that express SSRT. Nivolumab is an investigational agent that targets and inhibits a pathway that prevents your immune system from effectively fighting your cancer. The combination of these 2 study drugs is investigational. The term "Investigational" in this context means that the drugs have not been approved for clinical use by the US Food and Drug Administration (FDA).

Giving Lutathera and nivolumab together may increase the effectiveness of this therapy. We first need to find out the highest dose of Lutathera that can be given safely together with nivolumab. This study will be the first study to test giving Lutathera together with nivolumab. Once we have found the highest dose of Lutathera that can be given with nivolumab, we will treat more patients with this combination to determine how effective it is.

The purposes of this study are:

To find the highest doses of Lutathera that can be given with nivolumab without causing severe side effects.

To find out the side effects seen by giving Lutathera at different dose levels with nivolumab.

To determine if the amount of something in your tumor called PD-L1 makes you more likely to have a response to the combination of Lutathera and nivolumab.

Read the detailed description

The purpose of this project to see if the combination of 177Lu-DOTA0-Tyr3-Octreotate and nivolumab is safe and tolerable, and provides PFS benefit compared to observation alone in the maintenance setting in patients with ES-SCLC and no disease progression after first-line platinum-based chemotherapy.

Treatment will be administered on an outpatient basis. A standard dose-escalation phase I design will be used. Three subjects will be enrolled at each dose level in the absence of DLT.

Selection of the starting dose of 177Lu-DOTA0-Tyr3-Octreotate and nivolumab is based on the results from previous clinical studies with each compound used as single agent and the fact that the combination has not been tested in clinical trials. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Studies have shown that intravenous administration of amino acids has a renal protective effect [46]. An infusion of amino acids (lysine 2.5% and arginine 2.5% in 1 L 0.9% NaCl; 250 mL/h) will be started 30 minutes before the administration of 177Lu-DOTA0-Tyr3-Octreotate and last 4 hours.

Nivolumab will be administered as a fixed dose of 240 mg as an intravenous infusion over 30 minutes every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal or toxicities.

The phase II portion will consist of patients with ES-SCLC who completed platinum based standard first-line chemotherapy (e.g. 4-6 cycles of platinum plus etoposide or irinotecan) without disease progression (responders plus stable disease) at the time of initiation of the combination therapy with 177Lu-DOTA0-Tyr3-Octreotate and nivolumab. Eligible patients will then be randomly allocated in two arms: one will be treated with the combination of 177Lu-DOTA0-Tyr3-Octreotate and nivolumab, and the other arm will continue be followed (observation) after completion the standard chemotherapy treatment.

Randomization:

Patients who do not receive radiotherapy after chemotherapy

  • The randomization must occur within 6 weeks of the last chemotherapy cycle.
  • The study treatment must start within 2 weeks from randomization. Patients who receive radiotherapy (including prophylactic cranial radiation and/or thoracic radiation) after chemotherapy
  • The randomization must occur within 9 weeks of the last chemotherapy cycle but at least 2 weeks after completion of radiotherapy.
  • The first dose of 177Lu-DOTA0-Tyr3-Octreotate cannot be given within 8 weeks of radiotherapy.

Randomization process:

  • Randomization will be stratified according to NETSPOT® PET tumor uptake score (Grade 2, 3 and 4).
  • OnCore will be used as statistical center and the randomization algorithm will be developed by the study biostatistician.
  • The project management department will be the first point of contact for assessment through email.

Courses are defined as 56 days of dosing. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities. For patients randomized to the observation group, cross-over at the time of disease progression will be allowed, since the primary endpoint is PFS and not OS.

03

Conditions studied

  • Small Cell Lung Cancer
  • Small Cell Lung Cancer Extensive Stage

Keywords

  • nivolumab
  • 177Lu-DOTA0-Tyr3-Octreotate
  • Lutathera
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Phase I

Patients must have or histologically confirmed extensive-disease small-cell lung cancer (ES-SCLC) or non-progressing ES-SCLC after chemotherapy, or advanced or inoperable grade I-II pulmonary NETs.

Patients with tumor tissue uptake during NETSPOT® PET that is equal to or higher than that in normal hepatic tissue (grade ≥2) will be eligible. At the discretion of the principal investigator, patients with SCLC whose tumors have lower levels of uptake than liver during NETSPOT® PET may be eligible for the study.

Patients must have by criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan. See Section 7.1.2 for the evaluation of measurable disease.

Toxicities of prior therapy must be resolved to grade 1 or less as per (CTCAE) version 4.03 with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy.

Prior radiotherapy or radiosurgery (including prophylactic cranial radiation and/or thoracic radiation) must have been completed at least 2 weeks prior to randomization.

performance status of 0-1.

Adequate organ and bone marrow function ( > 9 g/dL; > 1.5 x 109/L; counts > 100 x 109/L; serum \< 2 x ; (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN or \< 5 x ULN if liver ; calculated > 50 mL/min).

of at least 3 months.

Age > 18 years.

Women of (WOCBP) must use avoid pregnancy for 23 weeks after the last dose of drug. Men who are sexually active with WOCBP must avoid pregnancy for 31 weeks after the last dose of investigational drug. Women who are not of childbearing potential (i.e., who are or surgically sterile as well as azoospermic men) are not required to avoid pregnancy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropic [HCG]) within 24 hours prior to the start of the study drug.

Women must not be pregnant or breastfeeding.

Ability to understand and willingness to sign a written document.

  • Phase II

Patients must have cytologically or histologically confirmed ES-SCLC and must not have progressed after first line platinum-based chemotherapy regimen before randomization.

Patients with tumor tissue uptake during NETSPOT® PET that is equal to or higher than that in normal hepatic tissue (grade ≥2) will be eligible. It is recommended that NETSPOT® PET be obtained before initiation of chemotherapy, but NETSPOT® PET obtained during or after completion of chemotherapy could be used for screening purpose.

Patients must have measurable disease by RECIST criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan. See Section 7.1.2 for the evaluation of measurable disease.

Toxicities of prior therapy must be resolved to grade 1 or less as per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 with the exception of alopecia and grade 2, prior platinum-therapy related neuropathy.

Prior radiotherapy or radiosurgery (including prophylactic cranial radiation and/or thoracic radiation) must have been completed at least 2 weeks prior to randomization.

For patients who do not receive radiotherapy after chemotherapy, the randomization must occur within 6 weeks of the last chemotherapy cycle. The study treatment must start within 2 weeks from randomization. For patients who receive radiotherapy (including prophylactic cranial radiation and/or thoracic radiation) after chemotherapy, the randomization must occur within 9 weeks of the last chemotherapy cycle but at least 2 weeks after completion of radiotherapy and the first dose of 177Lu-DOTA0-Tyr3-Octreotate cannot be given within 8 weeks of radiotherapy.

ECOG performance status of 0-1.

Adequate organ and bone marrow function (hemoglobin > 9 g/dL; absolute neutrophil count > 1.5 x 109/L; platelet counts > 100 x 109/L; serum bilirubin \< 2 x ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN or \< 5 x ULN if liver metastases; calculated creatinine clearance > 50 mL/min).

Life expectancy of at least 3 months.

Age > 18 years.

Women of childbearing potential (WOCBP) must use avoid pregnancy for 23 weeks after the last dose of investigational drug. Men who are sexually active with WOCBP must avoid pregnancy for 31 weeks after the last dose of investigational drug. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) are not required to avoid pregnancy. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropic [HCG]) within 24 hours prior to the start of the study drug.

Women must not be pregnant or breastfeeding.

Ability to understand and willingness to sign a written informed consent document.

Exclusion criteria

Exclusion Criteria:

  • Phase I

Subjects with active, known or suspected disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.

Subjects with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

Prior treatment with an , anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.

Patients with (HIV) infection, or active or C virus infection will be excluded.

Patients who received prior anti-tumoral radionuclide therapy (with unsealed sources) are not eligible for the study.

Prior major surgery within 12 weeks or prior major surgery from which the patient has not sufficiently recovered yet.

Untreated and uncontrolled second tumor in the past 2 years.

Logistical or psychological hindrance to participation in clinical research.

Uncontrolled or significant cardiovascular disease, including any of the following:

  • Symptomatic congestive heart failure ( Classification Class II).
  • Cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), or unstable angina.
  • Uncontrolled hypertension or uncontrolled cardiac arrhythmia.

Any other medical condition that in the Investigator's opinion would not make the patient a good candidate for the study.

  • Phase II

Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.

Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.

Patients with human immunodeficiency virus (HIV) infection, or active hepatitis B or C virus infection will be excluded.

Patients who received prior anti-tumoral radionuclide therapy (with unsealed sources) are not eligible for the study.

Prior major surgery within 12 weeks or prior major surgery from which the patient has not sufficiently recovered yet.

Untreated and uncontrolled second tumor in the past 2 years.

Logistical or psychological hindrance to participation in clinical research.

Uncontrolled or significant cardiovascular disease, including any of the following:

  • Symptomatic congestive heart failure (New York Heart Association Classification Class II).
  • Cerebral vascular accident/stroke (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), or unstable angina.
  • Uncontrolled hypertension or uncontrolled cardiac arrhythmia.

Any other medical condition that in the Investigator's opinion would not make the patient a good candidate for the study.

Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Phase II - Arm 1

    Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities. The Phase II dose of 177Lu-DOTA0-Tyr3-Octreotate will be the maximum tolerated dose as determined in the Phase I portion.

    Drug: Nivolumab · Radiation: 177Lu-DOTA0-Tyr3-Octreotate

  • Experimental
    Phase I - Dose Level -1

    Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities. 177Lu-DOTA0-Tyr3-Octreotate dose will be 3.7 GBq (100 mCi) every 8 weeks for 4 doses.

    Drug: Nivolumab · Radiation: 177Lu-DOTA0-Tyr3-Octreotate

  • Experimental
    Phase I - Dose Level 0

    Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities. 177Lu-DOTA0-Tyr3-Octreotate dose will be 7.4 GBq (200 mCi) every 8 weeks for 4 doses.

    Drug: Nivolumab · Radiation: 177Lu-DOTA0-Tyr3-Octreotate

  • No intervention
    Phase II - Arm 2

    Patients randomized to this arm will be followed (observation). Cross-over to Phase II Arm 1 at the time of disease progression will be allowed

Interventions

  • Nivolumab is administered intravenously

    Also known as: BMS-936558, Opdivo

  • Radiation177Lu-DOTA0-Tyr3-Octreotate

    177Lu-DOTA0-Tyr3-Octreotate will be administered every 8 weeks. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Each dose is infused over 30 minutes. On the day of 177Lu-DOTA0-Tyr3-Octreotate infusion, an intravenous bolus of anti-emetics will be given (suggested options: ondansetron (8 mg), granisetron (3 mg), or tropisetron (5 mg)). Administration of 177Lu-DOTA0-Tyr3-Octreotate may be given one day earlier or delayed up to 1 week due to holidays, inclement weather, conflicts, or similar reasons. Concurrent amino acids are given with each dose of 177Lu-DOTA0-Tyr3-Octreotate since co-infusion of amino acids leads to a significant reduction (47%) in the mean radiation dose to the kidneys. The amino acid solution and 177Lu-DOTA0-Tyr3-Octreotate are administered in parallel by peripheral vein infusion

    Also known as: Lutathera

06

What researchers measure

Primary outcomes

  1. Phase I - Recommended Phase II Dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate

    Maximum tolerated dose of 177Lu-DOTA0-Tyr3-Octreotate as determined during the phase I portion.

    Time frame: 12 months

  2. Phase II - Progression Free Survival

    Time between start of treatment and tumor progression or death

    Time frame: 12 months

Secondary outcomes

  1. Number of Participants With Treatment Related Adverse Events

    Adverse events and serious adverse events experienced by subjects

    Time frame: 24 months

  2. Phase II - Overall Survival

    Time between start of treatment and death

    Time frame: 24 months

  3. Phase II - Disease Control Rate

    The percentage of patients who achieve complete response, partial response and stable disease

    Time frame: 12 months

  4. Phase II - Objective Response Rate

    The proportion of patients with tumor size reduction

    Time frame: 12 months

  5. Phase II - Metabolic Response

    As measured by NETSPOT PET scan

    Time frame: 12 months

07

Results

Posted Mar 16, 2021

Participant flow

Participant flow — Overall Study
MilestonePhase I - Dose Level -1Phase I - Dose Level 0
Started36
Completed36
Not completed00

Outcome measures

PrimaryPhase I - Recommended Phase II Dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate

Maximum tolerated dose of 177Lu-DOTA0-Tyr3-Octreotate as determined during the phase I portion.

Time frame:
12 months
Reported as:
Number · GBq
Phase I - Recommended Phase II Dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate
GBqPhase I
Phase I - Recommended Phase II Dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate7.4
PrimaryPhase II - Progression Free Survival

Time between start of treatment and tumor progression or death

Time frame:
12 months

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Related Adverse Events

Adverse events and serious adverse events experienced by subjects

Time frame:
24 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related Adverse Events
ParticipantsPhase I - Dose Level -1Phase I - Dose Level 0
Number of Participants With Treatment Related Adverse Events36
SecondaryPhase II - Overall Survival

Time between start of treatment and death

Time frame:
24 months

No measurements were reported for this outcome.

SecondaryPhase II - Disease Control Rate

The percentage of patients who achieve complete response, partial response and stable disease

Time frame:
12 months

No measurements were reported for this outcome.

SecondaryPhase II - Objective Response Rate

The proportion of patients with tumor size reduction

Time frame:
12 months

No measurements were reported for this outcome.

SecondaryPhase II - Metabolic Response

As measured by NETSPOT PET scan

Time frame:
12 months

No measurements were reported for this outcome.

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I - Dose Level -10/3 (0%)2/3 (66.7%)3/3 (100%)
Phase I - Dose Level 00/6 (0%)2/6 (33.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventPhase I - Dose Level -1Phase I - Dose Level 0
Ventricular TachycardiaCardiac disorders1/30/6
HypoxiaRespiratory, thoracic and mediastinal disorders1/30/6
PneumonitisRespiratory, thoracic and mediastinal disorders0/31/6
Biliary Tract InfectionInfections and infestations0/31/6
Most frequent other events
Showing 10 of 47
Most frequent other events
EventPhase I - Dose Level -1Phase I - Dose Level 0
Aspartate aminotransferase increasedInvestigations2/32/6
Lymphocyte count decreasedInvestigations2/32/6
Platelet count decreasedInvestigations1/34/6
NauseaGastrointestinal disorders0/33/6
Abdominal PainGastrointestinal disorders1/31/6
Alanine aminotransferase increasedInvestigations1/32/6
AnemiaBlood and lymphatic system disorders1/32/6
ArthralgiaMusculoskeletal and connective tissue disorders1/31/6
Bronchial InfectionInfections and infestations1/30/6
ConstipationGastrointestinal disorders0/32/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase I - Dose Level -1Phase I - Dose Level 0Total
<=18 years000
Between 18 and 65 years156
>=65 years213
Sex: Female, Male
Sex: Female, Male(Participants)Phase I - Dose Level -1Phase I - Dose Level 0Total
Female055
Male314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase I - Dose Level -1Phase I - Dose Level 0Total
Hispanic or Latino000
Not Hispanic or Latino369
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase I - Dose Level -1Phase I - Dose Level 0Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American202
White167
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • Georgetown Lombardi Comprehensive Cancer Center
    Washington, District of Columbia 20007, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
09

References and documents

Publications

  • Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, Giaccone G. Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020 Jul;8(2):e000980. doi: 10.1136/jitc-2020-000980. PubMed 32616557 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2019, 16 months.

Results were first posted in Mar 2021, 1 year 11 months after primary completion.

Of 98 phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 97. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Oct 30, 2017
StartActual
Nov 20, 2017
Primary completionActual
Mar 28, 2019
CompletionActual
Aug 11, 2020
Results first posted
Mar 16, 2021
Last update
Mar 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03325816
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Nov 20, 2017
Primary completion
Mar 28, 2019
Completion
Aug 11, 2020
Results posted
Mar 16, 2021
Last update
Mar 16, 2021

Study contacts

Chul Kim, MD
principal investigator · Georgetown University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion